Metastatic triple-negative breast cancer
Clinical trials for Metastatic triple-negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new Metastatic triple-negative breast cancer trials appear
Sign up with your email to follow new studies for Metastatic triple-negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Two-Drug combo outsmart resistant breast and ovarian cancers?
Disease control Stopped earlyResearchers are testing whether combining ribociclib and belinostat can help people with metastatic triple-negative breast cancer or recurrent ovarian cancer. The trial starts by finding the safest dose of the drug pair, then expands to see how well it works in breast cancer pati…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising breast cancer drug trial stopped early
Disease control Stopped earlyThis study tested a drug called abemaciclib in 27 people with a specific type of advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the cancer's growth. The trial was terminated early, so results are limi…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cancer drug combo trial ends early – little known
Disease control Stopped earlyThis phase II trial tested a combination of two drugs, olinvacimab and pembrolizumab, in 19 women with metastatic triple-negative breast cancer. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so we have limited information on …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase 2 • Sponsor: PharmAbcine • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC